In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes

Journal of Chemotherapy

Volumn 18, Issue 4, 2006, Pages 379-388

  De Vecchi, E ^a   Nicola, L ^a   Zucchetti, E ^a   Drago, L ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Laboratory of Microbiology LITA   (Italy)

Author keywords

Amoxicillin clavulanate; Azithromycin; Cefixime; Clarithromycin; In vitro selection of resistance; Streptococcus pyogenes

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFIXIME; CLARITHROMYCIN; MACROLIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG DETERMINATION; DRUG INHIBITION; DRUG ISOLATION; DRUG SENSITIVITY; GENE FREQUENCY; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; PHENOTYPE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PYOGENES; TONSIL;

EID: 33749027188     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.4.379     Document Type: Article

References (42)

1. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002; 35: 113-25.
2. Mulla ZD. Invasive group A Streptococcus diseases. Clin Infect Dis 2002; 35: 1453.
3. Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Pediatric Drugs 2003; 5 (Suppl. 1): 35-46.
4. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J 1997; 16: 680-95.
5. Lowburry EJL, Hurst L. The sensitivity of staphylococci and other wound bacteria to erythromycin, oleandomycin and spiramycin. J Clin Pathol 1959; 12: 163-9.
6. Giovanetti E, Montanari MP, Mingoia M, Varaldo PE. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogenecity of inducibly resistant strains. Antimicrob Agents Chemother 1999; 43: 1935-40.
7. Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J, Doern GV; the GRASP Study Group. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 2005; 25: 148-56.
8. Green MD, Beall B, Marcon MJ. Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA. J Antimicrob Chemother 2006; 57: 1240-3.
9. Inoue M, Kaneko K, Akizawa K, et al. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002). J Infect Chemother. 2006; 12: 9-21.
10. Tamayo J, Perez-Trallero E, Gomez-Garces JL, Alos JI; Spanish Group for the Study of Infection in the Primary Health Care Setting. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother. 2005; 56: 780-2.
11. Seppala H, Klaukka M, Vuopio-Varkila J, et al, and the Finish study group for antimicrobial resistance. The effect of changes in the consumption of macrolide antibiotics on erythromycin-resistant in group A streptococci in Finland. N Engl J Med 1997; 337: 441-6.
12. Zampaloni C, Vitali LA, Prenna M, Toscano MA, Tempera G, Ripa S. Erythromycin resistance in Italian isolates of Streptococcus pyogenes and correlation with pulse-field gel electrophoresis analysis. Microb Drug Resist 2002; 8: 39-44.
13. Bergman M, Huikko S, Pihlajamaki M, et al; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis. 2004; 38: 1251-6.
14. Hsueh PR, Chen HM, Huang AH, Wu JJ. Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents Chemother 1995; 39, 2239-42.
15. Gagliotti C, Nobilio L, Milandri M, Moro ML; Emilia-Romagna Antibiotic Resistance Study Group. Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes. Clin Infect Dis. 2006; 42: 1153-6.
16. Cizman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents 2003; 21: 297-307.
17. Blondeau JM. Differential impact of macrolides compounds in the selection of macrolide nonsusceptible Streptococcus pneumoniae. Therapy 2005; 2: 813-18.
18. Schito GC, Pesce A, Marchese A. The role of macrolides in Streptococcus pyogenes pharyngitis. J Antimicrob Chemother 1997; 39: 562-565.
19. Ebell MH, Smith MA, Barry HC, Ives K, Carey M. The rational clinical examination. Does the patient have strep throat? JAMA 2000; 284: 2912-8.
20. Vincent MT, Celestin N, Hussain AN. Pharyngitis. Am Pham Phys 2004; 69: 1465-70.
21. National Committee for Clinical Laboratory Standards Document M7 - A6. Methods for Dilutions Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically. Sixth edition; Approved Standard. Wayne PA. NCCLS, 2003.
22. Fraschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, Demartini G. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother 1991; 27(Suppl A): 61-5.
23. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 (Suppl A): 73-82
24. Foulds G, Chan KH, Johnson JT, Shepard RM, Johnson RB. Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 1991; 10: 853-6.
25. Faulkner RD, Bohaychuk W, Desjardins RE et al. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J Clin Pharmacol 1987; 10: 807-12.
26. Begue P, Garabedian N, Quinet B, Baron S. Tonsillar diffusion of cefixime in children. Presse Med 1989; 32: 1593-5.
27. Fraschini F, Scaglione F, Falchi M et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990; 3: 171-7.
28. th informational supplement M100-S15. Wayne, PA. NCCLS.
29. Michèa Hamzehpour M, Kahr A, Pechère JC. In vitro stepwise selection of resistance to quinolones, β-lactams and amikacin in nosocomial Gram-negative bacilli. Infection 1994; 22 (Suppl. 2): S105-10.
30. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; (Suppl. 1): 35-43.
31. Tamayo J, Perez-Trallero E, Gomez-Garces JL, Alos JI, Spanish Group for the Study of Infection in the Primary Health Care Setting. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother 2005; 56: 780-2.
32. Reinert RR, Reinert S, van Der Linden M, Cil MY, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 2005; 49: 2903-13.
33. Leung AK, Kellner JD. Group A beta-hemolytic streptococcal pharyngitis in children. Adv Ther 2004; 21: 277-87.
34. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationship and dosage regimen. J Chemother 1999; 11: 11-27.
35. Anzueto A, Norris S. Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. Int J Antimicrob Agents 2004; 24: 1-17.
36. Portier H, Filipecki J, Weber P et al. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multicentre, open label, randomised study. J Antimicrob Chemother 2002; 49: 337-44.
37. Martin-Herrero JE, Garcia-Rey C, Dal-Ré R, Aguilar L. Clinical and bacteriological implications of macrolide resistance in group A streptococcal pharyngitis. J Antimicrob Chemother 2003; 52: 735-6.
38. Carsenti-Etesse H, Roger PM, Dunais B, et al. Gradient plate method to induce Streptococcus pyogenes resistance. J Antimicrob Chemother 1999; 44: 439-443.
39. Drago L, De Vecchi E, Nicola L, Colombo A, Gismondo M.R. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides. J Antimicrob Chemother 2004; 54: 542-545.
40. Noreddin AM, Roberts D, Nichol K, Wierzbowski A, Hoban DJ, Zhanel GG. Pharmacodynamic model of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial fluid free-drug concentrations. Antimicrob Agents Chemother 2002; 46:4029-34.
41. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes.Clin Infect Dis. 2004; 38 Suppl 4: S322-7.
42. Richter SS, Heilmann KP, Beekmann SE. Macrolide-Resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41:599-608.